Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sa-Hee Park"'
Autor:
Ita Novita Sari, Sanghyun Lee, Hyog Young Kwon, Yoseph Toni Wijaya, Nayoung Jun, Kwang Seock Kim, Jeevisha Bajaj, Soo-Hyun Kim, Sa-Hee Park, Tannishtha Reya, Jaeseok Han, Ying-Gui Yang, Vivian G. Oehler, Soo Young Choi, Dong-Wook Kim
Publikováno v:
Oncogene. 40:603-617
Polyamines are critical elements in mammals, but it remains unknown whether adenosyl methionine decarboxylase (AMD1), a rate-limiting enzyme in polyamine synthesis, is required for myeloid leukemia. Here, we found that leukemic stem cells (LSCs) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598c9d308d065e7df3f2d3fbe3c5ca53
https://doi.org/10.1038/s41388-020-01547-x
https://doi.org/10.1038/s41388-020-01547-x
Autor:
Jodi Braley, David T Yeung, Ilaria S. Pagani, David M. Ross, Susan Branford, Naranie Shanmuganathan, Timothy P. Hughes, Haley Altamura, Agnes S.M. Yong, Sa-Hee Park, Dong-Wook Kim, Devendra K Hiwase
With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR by improving our understanding of its key determinants. Chronic-phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c69cb41c5f382d22dda8d186602db83
https://hdl.handle.net/11541.2/146278
https://hdl.handle.net/11541.2/146278
Autor:
Martin C. Mueller, David M. Ross, David T Yeung, Andreas W. Schreiber, Timothy P. Hughes, Daniel Thomson, Jodi Braley, Nur Hezrin Shahrin, Wendy T Parker, Agnes S. M. Yong, Deborah L. White, Christian Dietz, Naranie Shanmuganathan, Jasmina Georgievski, Soo-Hyun Kim, Carol Wadham, Susan Branford, Dong-Wook Kim, Anna L. Brown, Joel Geoghegan, Adrian Purins, Justine E Marum, Jinghua Feng, Soo Young Choi, Christopher N. Hahn, Nathalie Nataren, Doris Stangl, Paul Wang, Hamish S. Scott, Haley Altamura, Sa-Hee Park, Ieuan Walker, Zoe R. Donaldson
Publikováno v:
Blood. 132(9)
Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are poorly understood. We performed whole-exome sequencing, copy-number variation, and/or RNA sequencing for 65 patients to discover mutations at diagnosis and blast crisis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6a355c41dc9868bbf29bc54936c443
https://pubmed.ncbi.nlm.nih.gov/30166361
https://pubmed.ncbi.nlm.nih.gov/30166361
Autor:
Michael Hayes, Dong-Wook Kim, Yu Jin, Horst Schran, Eren Demirhan, Sa-Hee Park, Yanfeng Wang, Eugene Y. Tan
Publikováno v:
British Journal of Clinical Pharmacology. 71:199-206
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Imatinib mesylate, a tyrosine kinase inhibitor, exhibits a weak competitive inhibition on paracetamol (acetaminophen) O-glucuronidation with an inhibition constant (Ki) value of 59 µm. However, the clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7f457f33174cb3f37f53cdc056b7221
https://doi.org/10.1111/j.1365-2125.2010.03810.x
https://doi.org/10.1111/j.1365-2125.2010.03810.x
Autor:
Jianbo He, Soo Young Choi, Bin Zhang, Sa-Hee Park, Puneet Agarwal, Dong-Wook Kim, David K. Crossman, Andrew Zhang, Ravi Bhatia, Su Chu
Publikováno v:
Blood. 132:1721-1721
Approximately half of chronic myeloid leukemia (CML) patients achieving deep molecular remission on tyrosine kinase inhibitors (TKIs) can successfully achieve treatment-free remission (TFR) after stopping TKI therapy. To gain insight into mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37b34c743e61a338a0a06fe2426d6fed
https://doi.org/10.1182/blood-2018-99-114137
https://doi.org/10.1182/blood-2018-99-114137
Autor:
Il-Young Kweon, Soo-Hyun Kim, Dong-Wook Kim, Nam Doo Kim, Wan-Seok Kim, Sa-Hee Park, Dongho Kim, Jeong Hyeok Yoon, Jeong Lee, Hyun-Gyung Goh, Haarin Chun, Byung-Sik Cho
Publikováno v:
Leukemia Research. 33:1260-1265
Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc928e87fc9c1bd441325b5df1cd875
https://doi.org/10.1016/j.leukres.2008.12.017
https://doi.org/10.1016/j.leukres.2008.12.017
Autor:
Hyun-Gyung Goh, Il-Young Kweon, Se-Eun Jang, Wan-Seok Kim, Jeong Lee, Dongho Kim, Hyeoung-Joon Kim, Dong-Wook Kim, Yoo-Jin Kim, Sa-Hee Park, Soo-Hyun Kim
Publikováno v:
Leukemia & Lymphoma. 50:944-951
Although imatinib is considered as a front line therapy in patients with chronic myeloid leukemia (CML), it is still unclear whether transient imatinib discontinuation may adversely affect the outcome. This study was conducted to investigate long-ter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1415755b3778eedfe6cea23e6bc1a23
https://doi.org/10.1080/10428190902926973
https://doi.org/10.1080/10428190902926973
Autor:
Ki-Sung Eom, Hyung-Ok Kim, Yun Ju Kim, Sung-Pil Lee, Min Ws, Seong-Beom Lee, S. G. Cho, Sa-Hee Park, Junguee Lee, Kim Dw, Chang-Ki Min
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e197-e198
e198 the occurrence of VTE), significant conversion of d-dimer from 2.2 0.4 mg/L to 11.8 1.6 mg/L (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8be112aee905afee26ddf7a997936798
https://doi.org/10.1016/j.clml.2015.07.433
https://doi.org/10.1016/j.clml.2015.07.433
Autor:
Soo-Hyun Kim, Hyun Gyung Goh, Dong-Wook Kim, Dongho Kim, Eun-Jung Jang, Soo Young Choi, Sa-Hee Park
Publikováno v:
International journal of hematology. 96(1)
Optimal responses during imatinib therapy are commonly defined following the European LeukemiaNet (ELN) recommendations. Achievements of these optimal responses have not, however, been comprehensively tested as response-related prognostic factors usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f6965a8bb7f2a3197b6ac083bc31e8f
https://pubmed.ncbi.nlm.nih.gov/22610512
https://pubmed.ncbi.nlm.nih.gov/22610512
Autor:
Wan-Seok Kim, Il-Young Kweon, Soo-Hyun Kim, Dong-Wook Kim, Sa-Hee Park, Hyun-Gyung Goh, Dongho Kim, Jeong Lee
Publikováno v:
Hematological oncology. 28(2)
We analysed the dynamic change of imatinib-resistant mutations in BCR-ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty-five imatinib-resistant chronic myeloid leukaemia patients (32 patients with imatinib-resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085e7da7884b72fccce0de793b2310fa
https://pubmed.ncbi.nlm.nih.gov/19768693
https://pubmed.ncbi.nlm.nih.gov/19768693